Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase.
Ronkin, S.M., Badia, M., Bellon, S., Grillot, A.L., Gross, C.H., Grossman, T.H., Mani, N., Parsons, J.D., Stamos, D., Trudeau, M., Wei, Y., Charifson, P.S.(2010) Bioorg Med Chem Lett 20: 2828-2831
- PubMed: 20356737 
- DOI: https://doi.org/10.1016/j.bmcl.2010.03.052
- Primary Citation of Related Structures:  
3G75, 3G7B, 3G7E - PubMed Abstract: 
Bacterial DNA gyrase is an attractive target for the investigation of new antibacterial agents. Inhibitors of the GyrB subunit, which contains the ATP-binding site, are described in this communication. Novel, substituted 5-(1H-pyrazol-3-yl)thiazole compounds were identified as inhibitors of bacterial gyrase. Structure-guided optimization led to greater enzymatic potency and moderate antibacterial potency. Data are presented for the demonstration of selective enzyme inhibition of Escherichia coli GyrB over Staphylococcus aureus GyrB.
Organizational Affiliation: 
Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139, USA. steven_Ronkin@vrtx.com